Steven Frank, MD
Dr. Frank is an endowed tenured professor of Radiation Oncology at The University of Texas MD Anderson Cancer Center, the Medical Director of MD Anderson’s Proton Therapy Center, and leader of both the Proton Therapy Program for head and neck cancer and the Prostate Brachytherapy Program. Dr. Frank also serves the Division as Director of Advanced Technologies in Radiation Oncology; he is amongst the first, if not the first, to use Intensity-Modulated Proton Therapy (IMPT) to treat head and neck tumors. Dr. Frank is the Principal Investigator of an NIH/NCI-sponsored Phase II/III randomized trial in oropharyngeal cancer that compares outcomes after chemoradiation given by IMRT versus IMPT. His other major clinical research accomplishment includes the successful accrual of 300 patients in a Phase II protocol for prostate cancer. Dr. Frank’s expertise in MRI radiotherapy has led to the development and FDA approval of a novel positive-contrast implantable marker for use in MRI-guided prostate brachytherapy. As founder of the company, C4 Imaging, Dr. Frank has developed the MRI marker technology at MD Anderson, currently holds 31 national and international patents and has continued MRI-Assisted Radiosurgery (MARS) at MD Anderson for the treatment of prostate cancer. He has funding from the NIH, the Prostate Cancer Foundation, the Texas Ignition Fund, Hitachi and MD Anderson, and he has also raised three rounds of private equity financing to advance C4 technology. Dr. Frank’s expertise in prostate brachytherapy is reflected by his service as past President and Chairman of the Board of the American Brachytherapy Society. Dr. Frank’s expertise in head and neck cancer has been acknowledged by his chairing the American Board of Radiology’s Oral Examinations Program for head and neck cancer.